okt 17, 2018: 2:15 p.m. - 3:10 p.m.
More than 60 biopharmaceutical acquisitions of private companies took place over the past four years. One of the greatest challenges faced by a leadership team is responding to an acquisition offer. The inability to predict when such an offer is likely to be received and the deadline pressure to react quickly heighten the importance of preparing for such scenarios in advance within a board of directors. Also, the inherent tension of boards including both venture investors and managers/founders may force difficult conversations regarding valuation and risk. This panel will review how to structure those conversations and decisions to be as productive as possible.%uFFFD
Moderator: Michael J. O%u2019Donnell, Partner, Morrison & Foerster LLP%uFFFD